• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泪腺多形性腺瘤临床病理特征及凋亡与增殖失衡致瘤机制的回顾性分析

Retrospective Analysis of Clinicopathological Characteristics of Lacrimal Gland Pleomorphic Adenoma and Mechanism of Tumorigenesis by the Imbalance Between Apoptosis and Proliferation.

作者信息

Lv Meng, Dong Zhi-Jun, Tong Yue-Xin, Li Tian, Hei Yan, Yang Xin-Ji, Dong Wei-Li

机构信息

Department of Ophthalmology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China (mainland).

Department of Minimally Invasive Spine Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China (mainland).

出版信息

Med Sci Monit. 2021 Mar 19;27:e929152. doi: 10.12659/MSM.929152.

DOI:10.12659/MSM.929152
PMID:33737504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7986817/
Abstract

BACKGROUND Lacrimal gland pleomorphic adenoma (LGPA) is the most common clinically benign epithelial tumor of the lacrimal gland and is predominantly comprised of epithelial cells and interstitial components. At present, the exact pathogenesis of LGPA remains unclear. Previous research has indicated that the occurrence of LGPA may be related to excessive cell proliferation. MATERIAL AND METHODS This study observed the clinicopathological characteristics of LGPA and investigated the tumorigenesis mechanism of cell over-proliferation caused by the imbalance between apoptosis and proliferation. A total of 27 cases were collected from the Department of Ophthalmology of the Affiliated Hospital of Chengde Medical University and the Third Medical Center of Chinese PLA General Hospital from April 2017 to November 2019. Hematoxylin-eosin (HE) staining and immunohistochemical staining were used to observe the pathological characteristics and analyze the expression of bcl-2 and bax in the lacrimal gland. RESULTS Compared with normal lacrimal gland tissues, LGPA tumor tissues had obvious changes in pathological morphology. The expression of bcl-2 in LGPA lesion tissues was dramatically higher (P<0.001), the expression of bax was not significantly different between groups (P=0.25), but the ratio of bcl-2/bax was significantly higher in tumor tissues (P=0.01). CONCLUSIONS We found that the lacrimal gland tumor tissues had obvious excessive proliferation in pathomorphology, which revealed the necessity of complete surgical removal of the capsule from the perspective of pathological morphology and provided a theoretical basis for the hypothesis that the imbalance between apoptosis and proliferation could lead to cell hyperproliferation.

摘要

背景 泪腺多形性腺瘤(LGPA)是临床上泪腺最常见的良性上皮性肿瘤,主要由上皮细胞和间质成分组成。目前,LGPA的确切发病机制尚不清楚。以往研究表明,LGPA的发生可能与细胞过度增殖有关。

材料与方法 本研究观察LGPA的临床病理特征,探讨凋亡与增殖失衡导致细胞过度增殖的肿瘤发生机制。2017年4月至2019年11月,从承德医学院附属医院眼科和中国人民解放军总医院第三医学中心共收集27例病例。采用苏木精-伊红(HE)染色和免疫组化染色观察病理特征,分析泪腺中bcl-2和bax的表达。

结果 与正常泪腺组织相比,LGPA肿瘤组织病理形态有明显改变。LGPA病变组织中bcl-2的表达显著升高(P<0.001),各组间bax的表达无显著差异(P=0.25),但肿瘤组织中bcl-2/bax的比值显著升高(P=0.01)。

结论 我们发现泪腺肿瘤组织在病理形态上有明显的过度增殖,从病理形态学角度揭示了完整手术切除包膜的必要性,并为凋亡与增殖失衡可导致细胞过度增殖这一假说提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/4f490c715d34/medscimonit-27-e929152-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/b48437662e70/medscimonit-27-e929152-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/51e83c9d0b6f/medscimonit-27-e929152-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/4f490c715d34/medscimonit-27-e929152-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/b48437662e70/medscimonit-27-e929152-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/51e83c9d0b6f/medscimonit-27-e929152-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2467/7986817/4f490c715d34/medscimonit-27-e929152-g003.jpg

相似文献

1
Retrospective Analysis of Clinicopathological Characteristics of Lacrimal Gland Pleomorphic Adenoma and Mechanism of Tumorigenesis by the Imbalance Between Apoptosis and Proliferation.泪腺多形性腺瘤临床病理特征及凋亡与增殖失衡致瘤机制的回顾性分析
Med Sci Monit. 2021 Mar 19;27:e929152. doi: 10.12659/MSM.929152.
2
Pleomorphic adenoma of the lacrimal gland: is there a role for biopsy?泪腺多形性腺瘤:活检有作用吗?
Eye (Lond). 2009 Jan;23(1):2-6. doi: 10.1038/eye.2008.16. Epub 2008 Mar 7.
3
Recurrent lacrimal gland pleomorphic adenoma: clinical and computed tomography features.复发性泪腺多形性腺瘤:临床和 CT 特征。
Ophthalmology. 2011 Oct;118(10):2088-92. doi: 10.1016/j.ophtha.2011.03.014.
4
A case of mistaken identity: the role of lacrimal gland pleomorphic adenoma tissue diagnosis.一例身份误诊病例:泪腺多形性腺瘤的组织诊断作用
Int Ophthalmol. 2018 Feb;38(1):381-384. doi: 10.1007/s10792-017-0445-2. Epub 2017 Jan 21.
5
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences.泪腺多形性腺瘤和恶性上皮肿瘤:临床和影像学差异。
Br J Ophthalmol. 2019 Feb;103(2):264-268. doi: 10.1136/bjophthalmol-2017-311538. Epub 2018 Apr 21.
6
Lacrimal gland pleomorphic adenoma: an inconceivable diagnosis in a child.泪腺多形性腺瘤:儿童中一种难以想象的诊断。
BMJ Case Rep. 2013 May 10;2013:bcr2013009138. doi: 10.1136/bcr-2013-009138.
7
Stereotactic radiosurgery for recurrent pleomorphic adenoma of the lacrimal gland: a case report.立体定向放射外科治疗复发性泪腺多形性腺瘤:一例报告
Acta Neurochir (Wien). 2023 Jan;165(1):221-224. doi: 10.1007/s00701-022-05384-7. Epub 2022 Oct 15.
8
Lacrimal gland pleomorphic adenoma with extensive necrosis.泪腺多形性腺瘤伴广泛坏死。
Orbit. 2022 Jun;41(3):378-381. doi: 10.1080/01676830.2020.1867194. Epub 2021 Jan 6.
9
Recurrent lacrimal gland pleomorphic adenoma.复发性泪腺多形性腺瘤。
Orbit. 2023 Dec;42(6):635-640. doi: 10.1080/01676830.2022.2064515. Epub 2022 May 12.
10
Lesions mimicking lacrimal gland pleomorphic adenoma.类似泪腺多形性腺瘤的病变。
Br J Ophthalmol. 2010 Nov;94(11):1509-12. doi: 10.1136/bjo.2008.156307.

引用本文的文献

1
Lacrimal gland pleomorphic adenoma: a narrative review.泪腺多形性腺瘤:一项叙述性综述
Arq Bras Oftalmol. 2022 Nov 4;87(3). doi: 10.5935/0004-2749.2022-0057.
2
The role of EphA7 in different tumors.EphA7 在不同肿瘤中的作用。
Clin Transl Oncol. 2022 Jul;24(7):1274-1289. doi: 10.1007/s12094-022-02783-1. Epub 2022 Feb 2.

本文引用的文献

1
Value of quantitative multiparametric MRI in differentiating pleomorphic adenomas from malignant epithelial tumors in lacrimal gland.定量多参数 MRI 在鉴别泪腺多形性腺瘤和恶性上皮性肿瘤中的价值。
Neuroradiology. 2020 Sep;62(9):1141-1147. doi: 10.1007/s00234-020-02455-3. Epub 2020 May 19.
2
Palpebral Pleomorphic Adenomas of the Lacrimal Gland.泪腺的眼睑多形性腺瘤。
Ophthalmic Plast Reconstr Surg. 2021;37(2):125-128. doi: 10.1097/IOP.0000000000001682.
3
Ectopic Lacrimal Gland Tissue: A Systematic Review.异位泪腺组织:系统评价。
Ophthalmic Plast Reconstr Surg. 2020 Nov/Dec;36(6):540-544. doi: 10.1097/IOP.0000000000001621.
4
Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.靶向抗凋亡BCL-2家族蛋白用于癌症治疗。
Future Med Chem. 2020 Apr;12(7):563-565. doi: 10.4155/fmc-2020-0004. Epub 2020 Feb 21.
5
[Diseases of the Lacrimal Gland].[泪腺疾病]
Klin Monbl Augenheilkd. 2020 May;237(5):703-723. doi: 10.1055/a-1068-7699. Epub 2020 Feb 3.
6
[Clinical features and pathological analysis of lacrimal gland occupying lesions in 91 cases].91例泪腺占位性病变的临床特征及病理分析
Zhonghua Yan Ke Za Zhi. 2019 Nov 11;55(11):842-846. doi: 10.3760/cma.j.issn.0412-4081.2019.11.010.
7
Immunohistochemical features of carcinoma ex pleomorphic adenoma and pleomorphic adenoma in the lacrimal gland.泪腺多形性腺瘤癌变及多形性腺瘤的免疫组化特征
Int J Ophthalmol. 2019 Aug 18;12(8):1238-1242. doi: 10.18240/ijo.2019.08.02. eCollection 2019.
8
Clinicopathologic features of biopsied lacrimal gland masses in 95 Korean patients.95例韩国患者泪腺肿物活检的临床病理特征
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1527-1533. doi: 10.1007/s00417-019-04327-w. Epub 2019 Apr 25.
9
[Benign Neoplasms of the Orbit].[眼眶良性肿瘤]
Klin Monbl Augenheilkd. 2019 Jul;236(7):929-947. doi: 10.1055/a-0885-2402. Epub 2019 Apr 18.
10
The impact of proliferation-migration tradeoffs on phenotypic evolution in cancer.增殖-迁移权衡对癌症表型进化的影响。
Sci Rep. 2019 Feb 20;9(1):2425. doi: 10.1038/s41598-019-39636-x.